Login
$STTK
$4.66 +$0.01 (0.22%) Live

Company Executives

Officer Age In this role 2025 pay Source
Taylor Schreiber Also a director
Chief Executive Officer and Director
46 Not stated $1,532,763
Andrew R. Neill
Chief Financial Officer
40 Since 2021
5 years
$883,433
Abhinav Shukla
Chief Technical Officer
53 Since 2021
5 years
Not reported
Arunthathy Nirmalini (Lini) Pandite
Chief Medical Officer
67 Since 2017
9 years
$932,645
Casi DeYoung
Chief Business Officer
55 Since 2019
7 years
Not reported
Arundathy N. Pandite
Chief Medical Officer
Title from the Form 4 dated Jun 30, 2026
Not stated Not stated Not reported
Stephen Stout
See Remarks
Title from the Form 4 dated May 15, 2026
51 Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
5.3 years
from year joined
CEO also chairs the board
No
George Golumbeski, Ph.D.
Director Age On board Independent Other public boards 2025 pay Source
George Golumbeski, Ph.D.
68 2018
8 years
Independent Sage Therapeutics, Inc., Mural Oncology $99,677
Taylor Schreiber, M.D., Ph.D.
46 2017
9 years
Not independent None stated Paid as CEO
Mona Ashiya, Ph.D.
57 2025
1 year
Independent Yarrow Bioscience, Inc. $68,694
Daniel Baker, M.D.
75 2025
1 year
Independent None stated $72,528
Helen M. Boudreau
60 2020
6 years
Independent Rallybio Corp. $77,177
Neil Gibson, Ph.D.
69 2016
10 years
Independent TCR2 Therapeutics Inc., Causeway Therapeutics, Adanate, Inc., Instil Bio, Inc. $77,677
Clay Siegall, Ph.D.
65 2024
2 years
Independent Immunome, Inc. $68,844

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 8, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support